-
公开(公告)号：KR102241938B1
公开(公告)日：2021-04-20
申请号：KR1020200117862
申请日：2020-09-14
Applicant: (주)에이피테크놀로지
IPC: A23L33/125 , A23L29/281
Abstract: 본발명은혈전의생성으로말미암은여러뇌심혈관질환에효과가있는 2'-푸코실락토오스함유식품조성물에관한것으로, 본발명의 2'-푸코실락토오스(2'-fucosyllactose, 2'-FL)는혈소판에대한아고니스트인 CRP(collagen-related peptide), 콜라겐에대해서길항(저해) 작용을나타내어, 혈소판의비정상적작용에의한혈전의생성을억제하는데사용될수 있다.
-
-
公开(公告)号：KR101960501B1
公开(公告)日：2019-03-21
申请号：KR1020170118313
申请日：2017-09-15
Applicant: 고려대학교 산학협력단 , (주)에이피테크놀로지
-
Patent Agency Ranking
公开(公告)号：KR101814048B1
公开(公告)日：2018-01-02
申请号：KR1020140010183
申请日：2014-01-28
Applicant: (주)에이피테크놀로지
Abstract: 본발명은경구투여용약제개발시필수적으로요구되는대량생산이가능하도록개량된경구투여용트롬보포이에틴및 이의대량생산공정에관한것으로, 대장균내에서발현이잘 되지않는서열번호 1에기재된 '단백질분해효소저항성개량트롬보포이에틴'에유비퀴틴및 히스택을융합시켜불용성내포체형태로성공적으로발현시켰고, 수용화공정, 융합파트너제거공정, 리간드친화성크로마토그래피, 이온교환크로마토그래피를이용한정제공정을통해고순도의활성형형태로대량수득하는데성공하였다.
Abstract translation: 根据于，SEQ ID NO本发明的“蛋白：1在大肠杆菌中表达的开发药物用于口服给药的过程中血小板生成素的口服给药，和用于改善其大规模生产过程不工作，以使大量生产所需的必不可少的 酶抗性提高血小板生成素“的遍在蛋白和sikyeotgo熔断器也希斯选择成功表达如在我的FOCE型不溶性的，接收降低的过程中，融合配偶体除去步骤中，配体亲和色谱法，使用离子交换色谱法的纯化方法 以高纯度活性形式。
-
公开(公告)号：KR100983324B1
公开(公告)日：2010-09-20
申请号：KR1020080076540
申请日：2008-08-05
Applicant: 충북대학교 산학협력단 , (주)세전 , (주)에이피테크놀로지
Abstract: 본 발명은 L-아라비노스가 함유된 고분자 중합체를 포함하는 기질 액에, 엑소 타입의 가수분해효소인 아라비노퓨라노시다아제를 처리하여 L-아라비노스를 분리하는 방법에 있어서, KCl 또는 NaCl을 첨가하여 반응시키는 것을 특징으로 하는 효소 분해법에 의한 L-아라비노스의 분리 방법에 관한 것으로, KCl 또는 NaCl을 첨가함으로써 아라비노퓨라노시다아제의 반응 활성을 높여 L-아라비노스를 선택적으로 분리할 수 있으며, 농업 부산물을 재활용하여 처리비용을 절감하고 환경오염을 줄일 수 있는 효과를 발휘한다.
L-아라비노스, 아라비노퓨라노시다아제, 아라비노자일란, 아라비난-
公开(公告)号：KR1020100096038A
公开(公告)日：2010-09-01
申请号：KR1020100016400
申请日：2010-02-23
Applicant: 성균관대학교산학협력단 , (주)에이피테크놀로지
IPC: A61K9/127 , A61K31/122 , A61K31/575 , A61K47/48
CPC classification number: A61K9/1275 , A61K9/127 , A61K31/122 , A61K31/575 , A61K47/50
Abstract: PURPOSE: A method for preparing an insoluble drug nanocomplex is provided to enhance manufacture yield of the insoluble drug nanocomplex. CONSTITUTION: A method for preparing an insoluble drug nanocomplex comprises: a step of dissolving insoluble drug in a solvent containing surfactant; a step of adding apolipoprotein in the solution; a step of heating the solution; and a step of removing surfactant and solvent from the solution. The insoluble drug is dissolved with phospholipid. The phospholipid is phosphatidylcholine. The insoluble drug is coenzyme Q10, ursodeoxycholic acid, ilaprazole, paclitaxel or imatinib mesylate. The surfactant is cholic acid or salt thereof. The apolipoprotein is apolipotprotein A-I.
Abstract translation: 目的：提供一种制备不溶性药物纳米复合物的方法，以提高不溶性药物纳米复合物的制造成品率。 构成：制备不溶性药物纳米复合物的方法包括：将不溶性药物溶解在含有溶剂的表面活性剂中的步骤; 在溶液中加入载脂蛋白的步骤; 加热溶液的步骤; 以及从溶液中除去表面活性剂和溶剂的步骤。 不溶性药物用磷脂溶解。 磷脂是磷脂酰胆碱。 不溶性药物是辅酶Q10，熊去氧胆酸，伊拉唑，紫杉醇或甲磺酸伊马替尼。 表面活性剂是胆酸或其盐。 载脂蛋白是载脂蛋白A-I。
-
公开(公告)号：KR1020100016893A
公开(公告)日：2010-02-16
申请号：KR1020080076540
申请日：2008-08-05
Applicant: 충북대학교 산학협력단 , (주)세전 , (주)에이피테크놀로지
CPC classification number: C12P19/02 , C12P19/14 , C12Y302/01055
Abstract: PURPOSE: A method for isolating L-arabinose through enzyme hydrolysis is provided to ensure reaction activity of enzyme by adding KCl or NaCl and selectively isolate L-arabinose. CONSTITUTION: An L-arabinose is isolated by treating arabinofuranosidase to a substrate liquid containing polymer having L-arabinose. The arabinofuranosidase reactivity is enhanced by adding KCl or NaCl. The polymer having the L-arabinose is a polymer having L-arabinose of homo form or hetero form. The polymer containing L-arabinose of homo form is arabinan. The polymer having L-arabinose of hetero form is arabinoxylan.
Abstract translation: 目的：提供通过酶水解分离L-阿拉伯糖的方法，通过加入KCl或NaCl并选择性分离L-阿拉伯糖来确保酶的反应活性。 构成：通过将阿拉伯呋喃糖苷酶处理成含有L-阿拉伯糖的聚合物的底物液体来分离L-阿拉伯糖。 通过加入KCl或NaCl增强阿拉伯呋喃糖苷酶的反应活性。 具有L-阿拉伯糖的聚合物是具有同形或异形的L-阿拉伯糖的聚合物。 含有同形型的L-阿拉伯糖的聚合物是阿拉伯聚糖。 具有异形态的L-阿拉伯糖的聚合物是阿拉伯木聚糖。
-
公开(公告)号：KR1020040033143A
公开(公告)日：2004-04-21
申请号：KR1020020062055
申请日：2002-10-11
Applicant: 한남수 , (주)에이피테크놀로지
IPC: C12N9/24
CPC classification number: C12N9/2402 , C12P19/02 , C12Y302/01055
Abstract: PURPOSE: Arabinofuranosidase produced from Thermotoga maritima and a method for producing arabinose using the same are provided, thereby specifically digesting the side chains of arabinoxylan to inhibit the production of by-products, and improving the production rate and yield of arabinose by conducting the enzyme reaction at high temperature. CONSTITUTION: Alpha-L-arabinofuranosidase produced from Thermotoga maritime has optimal operation temperature of 60 to 120 deg. C and optimal operation pH of 4 to 9, and specifically digests arabinoxylan to produce arabinose, wherein the alpha-L-arabinofuranosidase has the amino acid sequence set forth in SEQ ID NO: 2; and a gene encoding the alpha-L-arabinofuranosidase has the nucleotide sequence set forth in SEQ ID NO: 1. A method for producing arabinose comprises digesting the substrate containing arabinose with the alpha-L-arabinofuranosidase of Thermotoga maritime.
Abstract translation: 目的：提供由Thermotoga maritima产生的阿拉伯呋喃糖苷酶和使用该方法生产阿拉伯糖的方法，从而特异性消化阿拉伯木聚糖的侧链以抑制副产物的产生，并通过进行酶反应来提高阿拉伯糖的产生速率和产量 在高温下。 构成：由Thermotoga maritime生产的Alpha-L-阿拉伯呋喃糖苷酶具有60至120度的最佳操作温度。 并且最佳操作pH为4至9，并且具体地消化阿拉伯木聚糖以产生阿拉伯糖，其中所述α-L-阿拉伯糖苷酶具有SEQ ID NO：2所示的氨基酸序列; 并且编码α-L-阿拉伯呋喃糖苷酶的基因具有SEQ ID NO：1所示的核苷酸序列。用于产生阿拉伯糖的方法包括用Thermotoga maritime的α-L-阿拉伯呋喃糖苷酶消化含有阿拉伯糖的底物。
-
-
-
-
-
-
-
Search Results
28
records
(took 0.023 seconds)
